Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 6/2002

01-12-2002 | Original Article

Clinical pharmacokinetics, pharmacodynamics and metabolism of the novel matrix metalloproteinase inhibitor ABT-518

Authors: Mirjam Crul, Laurens V. Beerepoot, Ellen Stokvis, Johannes S. Vermaat, Hilde Rosing, Jos H. Beijnen, Emile E. Voest, Jan H. Schellens

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2002

Login to get access
Metadata
Title
Clinical pharmacokinetics, pharmacodynamics and metabolism of the novel matrix metalloproteinase inhibitor ABT-518
Authors
Mirjam Crul
Laurens V. Beerepoot
Ellen Stokvis
Johannes S. Vermaat
Hilde Rosing
Jos H. Beijnen
Emile E. Voest
Jan H. Schellens
Publication date
01-12-2002
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 6/2002
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-002-0515-6

Other articles of this Issue 6/2002

Cancer Chemotherapy and Pharmacology 6/2002 Go to the issue

Original Article

Cytosolic and microsomal activation of doxifluridine and tegafur to produce 5-fluorouracil in human liver

Original Article

Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol

Original Article

Decreased tumor blood flow as measured by positron emission tomography in cancer patients treated with interleukin-1 and carboplatin on a phase I trial

Original Article

In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines

Original Article

Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia

Short Communication

Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits